Peptonic Medical files patent application for the treatment of vulvar vestibulitis syndrome with VagiVital®

  • -

Peptonic Medical AB (publ) (‘Peptonic’ or the ‘Company’) today announced that the Company has filed a patent application concerning the use of its self-care vaginal gel VagiVital®for the treatment of vulvar vestibulitis syndrome (VVS). The background of this potential indication expansion is the pronounced symptom relief experienced by many women suffering from VVS after having used VagiVital®. In a recently conducted survey among women that had been diagnosed with VVS the proportion of respondents that rated their VVS symptoms as ‘unbearable’ or ‘severe’ decreased from 71 to 24 per cent after having used VagiVital® for one month or longer.

– These results were very encouraging, even surprisingly positive, says Johan Inborr, CEO of Peptonic Medical. 

The Company is now investigating the possibilities for conducting a clinical study with women that have been diagnosed with VVS.

VagiVital® is a CE-marked product indicated for the treatment of symptoms associated with vaginal atrophy. 

For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
E-mail:  johan.inborr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7th May, 2020.


About vulvar vestibulitis syndrome

Vulvar vestibulitis syndrome (VVS), vestibulodynia, or vulvar vestibulitis, is vulvodynia localized to part or the whole of the vulvar vestibule. The symptoms of vestibulodynia includes a localized burning, aching, itching or cutting kind of pain in the vestibular area, often in connection with touching or applying a pressure on this area. The pain may be provoked by e.g. the insertion of a tampon or a penis or with the pressure from sitting, or it may be constant. The pain may occur at the first penetration (primary vulvar vestibulitis) or after a period of time with pain-free penetration (secondary vulvar vestibulitis).

Little is known about the cause of vestibulodynia. It has been speculated that sub-clinical human papillomavirus infection, chronic recurrent candidiasis, or chronic recurrent bacterial vaginosis may be involved. Also, muscular causes have been suggested, as a result of chronic hypertonic perivaginal muscles, leading to vaginal tightening and pain. In addition, neurological causes have been implied. Psychological factors may contribute to or increase the problem, leading to a lowered sex drive and difficulties in becoming aroused. 

Medications to lessen the symptoms of vestibulodynia typically include local anaesthetics, estrogen treatment, nerve blocks, anti-inflammatory medications (e.g. steroids) and botox, i.e. botulinum toxin. Also, muscular exercise of the vaginal and pelvic muscles, transcutaneous electrical nerve stimulation, and even surgery to remove painful tissue have been used as therapies for vestibulodynia. 

About  VagiVital®

VagiVital® is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects. 

VagiVital® was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com).  

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital® is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlightstockmarket.se, ticker: PMED) in Stockholm, Sweden. 

For more information: www.peptonicmedical.com